ReviewFrontiers in neurology2016
Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging.
Review in Frontiers in neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018Pooled it
- Therapeutic reactivation of hippocampal progenitors reverse cognition decline in mice with progressive brain demyelination.Stem cell reports · 2026Article
- Regional distribution of an amyloid radiotracer in healthy aged human brain measured by PET with [Annals of nuclear medicine · 2026Article
- Baseline Findings from Dual-Phase Amyloid PET Study in Newly Diagnosed Multiple Sclerosis: Exploring Its Potential as a Biomarker of Myelination and Neurodegeneration.Journal of personalized medicine · 2025Article
- Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosis.Brain communications · 2024Article
- Identification of protein-protein interaction bridges for multiple sclerosis.Bioinformatics (Oxford, England) · 2023Article
- Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage.Alzheimer's research & therapy · 2022Article
- The Cause of Alzheimer's Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress.Aging and disease · 2022Article
- Proteomics of Multiple Sclerosis: Inherent Issues in Defining the Pathoetiology and Identifying (Early) Biomarkers.International journal of molecular sciences · 2021Review
- [European journal of nuclear medicine and molecular imaging · 2020Article
- Genetic Alterations in Patients with Two Clinical Phenotypes of Multiple Sclerosis.Journal of molecular neuroscience : MN · 2020Article
- Particles Containing Cells as a Strategy to Promote Remyelination in Patients With Multiple Sclerosis.Frontiers in neurology · 2020Review
- CD8+ T Cell-Mediated Mechanisms Contribute to the Progression of Neurocognitive Impairment in Both Multiple Sclerosis and Alzheimer's Disease?Frontiers in immunology · 2020Review
- Article
- Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes.European journal of nuclear medicine and molecular imaging · 2019Article
- A new frontier for amyloid PET imaging: multiple sclerosis.European journal of nuclear medicine and molecular imaging · 2019Article
- β-Amyloid precursor protein (APP) and the human diseases.AIMS neuroscience · 2019Review
- Machine-learning based lipid mediator serum concentration patterns allow identification of multiple sclerosis patients with high accuracy.Scientific reports · 2018Article
- Identification of brain antigens recognized by autoantibodies in experimental autoimmune encephalomyelitis-induced animals treated with etomoxir or interferon-β.Scientific reports · 2018Article
- Special Issue: Alzheimer's disease.AIMS neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thioflavin T derivatives are used in positron-emission tomography (PET) studies to detect amyloid protein deposits in patients with Alzheimer disease. These tracers bind extensively to white matter, which suggests that they may be useful in studies of multiple sclerosis (MS), and that proteins resulting from proteolytic processing of the amyloid precursor protein (APP) may contribute to MS. This article reviews data from both clinical and preclinical studies addressing the role of these proteins, whether they are detected in CSF studies or using PET imaging. APP is widely expressed in demyelinated axons and may have a protective effect in MS and in experimental allergic encephalomyelitis in animals. Several mechanisms associated with this increased expression may affect the degree of remyelination in MS. Amyloid-PET imaging may help determine the degree of demyelination and provide information on the molecular changes linked to APP proteolytic processing experienced by patients with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.